ACC/AHA/NHLBI clinical advisory on the use and safety of statins

Richard C. Pasternak, Sidney C. Smith, C. Noel Bairey-Merz, Scott M Grundy, James I. Cleeman, Claude Lenfant

Research output: Contribution to journalReview article

420 Scopus citations

Abstract

Statin therapy holds great promise for reducing the incidence of major coronary events, coronary procedures, and stroke in high-risk patients. At present, this potential has not been fully realized, because many patients at heightened risk are not being treated with these drugs. There is a well documented under-use of statins in clinical practice. Statins have proven to be extremely safe in the vast majority of patients receiving them. Few significant side effects were observed in clinical trials, and post-marketing reports of adverse events have been very limited when considered in comparison to the very large number of persons safely receiving these drugs. Even so, these drugs are not entirely free of side effects, and as for all drugs, they should be used appropriately and judiciously. This advisory encourages the appropriate use of statins while pointing out the possibility of side effects in certain patients. If statins are used with appropriate caution in these selected patients, the likelihood of developing clinically important myopathy should be substantially reduced. (See Tables 1 and 2.).

Original languageEnglish (US)
Pages (from-to)1024-1028
Number of pages5
JournalCirculation
Volume106
Issue number8
DOIs
StatePublished - Aug 20 2002

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Fingerprint Dive into the research topics of 'ACC/AHA/NHLBI clinical advisory on the use and safety of statins'. Together they form a unique fingerprint.

  • Cite this

    Pasternak, R. C., Smith, S. C., Bairey-Merz, C. N., Grundy, S. M., Cleeman, J. I., & Lenfant, C. (2002). ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation, 106(8), 1024-1028. https://doi.org/10.1161/01.CIR.0000032466.44170.44